Preliminary Research On Bozhi Glycopeptides Efficacy In Human Keratinocyte Cell Suppression And Anti-psoriasis

There has been an upward trend in recent years towards researches on commoninflammatory diseases including psoriasis due to the incidences of these diseases areon the rise. Psoriasis, known as a cancer not unto death, is a common, chronic skindisease characterized by thick red plaques covered with silvery scales, systemicinflammatory damage and secondary infection, usually affecting areas like scalp andlimps. In severe cases, it may lead to problems including nutrient depletion, organ andjoint damage, and, moreover, endangering the patient’s life. Therefore, it has becomea major research topic as well as one of the key tasks for disease prevention andtreatment in global dermatology. In addition, psoriasis is a common recurrent diseaseof low curability and profoundly impaired quality of life. Until now, the fundamentalpathophysiology of the disease still has not been fuLly elucidated. Nowadays, thereare various treatments options, which include the combination of traditional Chineseand Western medicine, as well as the internal and external therapies togethercombined with physical therapy. Along with balanced diet, more exercises and mentalhealth maintenance, it is essential to develop new effective antipsoriatics to relievepatients’symptoms.Objectives: Psoriasis is a common, chronic, inflammatory skin diseasecharacterized by keratinocyte hyperplasia. In order to discuss whether Bozhiglycopeptides can relive symptoms of or cure psoriasis by suppressing keratinocytehyperplasia, we combined it with IL-6, IL-22, TNF-α respectively to treat HacaT cells,whose celluLar viability, gene and protein expressions associated with psoriasis wereexamined in order to preliminarily investigate the suppression effect of Bozhiglycopeptides on the proliferation of keratinocyte. Methods:(1) After treating HacaTcells using Bozhi glycopeptides with IL-6, IL-22and TNF-α respectively, we usedCell Counting Kit-8(CCK-8) to detect their proliferation rates;(2) Using Western blotto detect expressions of K16, K17and Involucrin;(3)Using Real-time quantitativePCR to detect expressions of hBD-2and IL-8mRNA. ResuLts: We divided theHacaT cells into6groups to receive either IL-6, IL-22, TNF-α, IL-6+Bozhi glycopeptides, IL-22+Bozhi glycopeptides, or TNF-α+Bozhi glycopeptides.(1)CCK-8test resuLts: Compared with blank group, the proliferation rates of HacaTcells in all the6treatment groups were significantly, in which group IL-6+Bozhiglycopeptides, IL-22+Bozhi glycopeptides and TNF-α+Bozhi glycopeptidespresented proliferations lower than that of group IL-6, IL-22and TNF-α. Moreover,we found that the optimal drug concentration of Bozhi glycopeptides is75ug/ml;(2)Western blot analysis resuLts: Compared with blank group, HacaT cell expressions ofK16, K17and Involucrin showed significant increment after48h in the above6groups respectively, especially that of Involucrin. However, when we regarded groupIL-6, IL-22and TNF-α as control groups, group IL-6+Bozhi glycopeptides, IL-22+Bozhi glycopeptides and TNF-α+Bozhi glycopeptides displayed decrement in theirprotein expressions;(3) Real-time quantitative PCR resuLts: Compared to blankgroup, all of the6groups demonstrated higher HBd-2/IL-8mRNA expression, whilepresenting lower mRNA expression in group IL-6+Bozhi glycopeptides, IL-22+Bozhi glycopeptides and TNF-α+Bozhi glycopeptides. Conclusions: Bozhiglycopeptides has the ability to treat psoriasis by reguLating and suppressingkeratinocyte hyperplasia as well as restoring the balance among differentiation,proliferation and apoptosis in keratinocytes.